{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:06:03Z","timestamp":1791461163933,"version":"4.3.4"},"reference-count":236,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202008510141"],"award-info":[{"award-number":["202008510141"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022238","name":"LabEx DEvweCAN","doi-asserted-by":"publisher","award":["ANR-10-LABX #0061"],"award-info":[{"award-number":["ANR-10-LABX #0061"]}],"id":[{"id":"10.13039\/501100022238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022238","name":"LabEx DEvweCAN","doi-asserted-by":"publisher","award":["2024\\u2013132"],"award-info":[{"award-number":["2024\\u2013132"]}],"id":[{"id":"10.13039\/501100022238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011074","name":"Universit\u00e9 de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006687","name":"Universite Claude Bernard Lyon 1","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118741","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T16:18:08Z","timestamp":1763050688000},"page":"118741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Exploring and bypassing resistance to targeted therapies in colorectal cancer"],"prefix":"10.1016","volume":"193","author":[{"given":"Sol\u00e8ne","family":"Favier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounira","family":"Chalabi-Dchar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Chettab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Piercey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanguy","family":"Fenouil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Alexandra","family":"Albaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Petter","family":"Jordheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Hollande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dumontet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5958-6662","authenticated-orcid":false,"given":"Hichem C.","family":"Mertani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118741_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA","volume":"71","author":"Sung","year":"2021","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.biopha.2025.118741_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1089\/154099903321576574","article-title":"Diet, body weight, and colorectal cancer: a summary of the epidemiologic evidence","volume":"12","author":"Giovannucci","year":"2003","journal-title":"J. Women\u2019s. Health"},{"key":"10.1016\/j.biopha.2025.118741_bib3","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1136\/gutjnl-2019-319511","article-title":"Global patterns and trends in colorectal cancer incidence in young adults","volume":"68","author":"Siegel","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2025.118741_bib4","unstructured":"F.E. Vuik, S.A. Nieuwenburg, M. Bardou, I. Lansdorp-Vogelaar, M. Dinis-Ribeiro, M.J. Bento, V. Zadnik, M. Pellis\u00e9, L. Esteban, M.F. Kaminski, S. Suchanek, O. Ngo, O. M\u00e1jek, M. Leja, E.J. Kuipers, M.C. Spaander, Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years, (n.d.)."},{"key":"10.1016\/j.biopha.2025.118741_bib5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2025.118741_bib6","unstructured":"The Cancer Genome Atlas Program (TCGA) - NCI, (2022)."},{"key":"10.1016\/j.biopha.2025.118741_bib7","unstructured":"ICGC ARGO, (n.d.)."},{"key":"10.1016\/j.biopha.2025.118741_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2025.118741_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12943-025-02323-9","article-title":"Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment","volume":"24","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","article-title":"Metastatic colorectal cancer: mechanisms and emerging therapeutics","volume":"44","author":"Shin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2025.118741_bib13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling\u00a0? in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2025.118741_bib14","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs Bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2025.118741_bib15","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase IIi randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib16","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib17","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3390\/ijms19041232","article-title":"Resistance to anti-angiogenic therapy in cancer\u2014alterations to anti-VEGF pathway","volume":"19","author":"Itatani","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118741_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100156","article-title":"Strategies to tackle RAS-mutated metastatic colorectal cancer","volume":"6","author":"Patelli","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.biopha.2025.118741_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118741_bib20","unstructured":"FDA Approves First Angiogenesis Inhibitor To Treat Colorectal Cancer, ScienceDaily, (n.d.)."},{"key":"10.1016\/j.biopha.2025.118741_bib21","unstructured":"M.D. James L. Abbruzzese, 2004 Sees FDA Approval of Two Tumor Growth Inhibitors for Colorectal Cancer, 13 (2004)."},{"key":"10.1016\/j.biopha.2025.118741_bib22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.12-5-577","article-title":"FDA drug approval summary: panitumumab (Vectibix)","volume":"12","author":"Giusti","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2025.118741_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2147\/CMAR.S88825","article-title":"Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a \u201cme too\u201d drug?","volume":"10","author":"Goel","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.biopha.2025.118741_bib24","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1684\/bdc.2013.1807","article-title":"Aflibercept (Zaltrap(\u00ae)) approved in metastatic colorectal cancer]","volume":"100","author":"Andr\u00e9","year":"2013","journal-title":"Bull. Cancer (Paris)"},{"key":"10.1016\/j.biopha.2025.118741_bib25","unstructured":"FDA Approves Ramucirumab for Second-Line Treatment of mCRC, Cancer Netw., (2015)."},{"key":"10.1016\/j.biopha.2025.118741_bib26","unstructured":"C. for D.E. and Research, FDA grants nivolumab accelerated approval for MSI-H or dMMR colorectal cancer, FDA, (2024)."},{"key":"10.1016\/j.biopha.2025.118741_bib27","unstructured":"C. for D.E. and Research, FDA grants accelerated approval to ipilimumab for MSI-H or dMMR metastatic colorectal cancer, FDA, (2024)."},{"key":"10.1016\/j.biopha.2025.118741_bib28","unstructured":"FDA Approves Encorafenib for Colorectal Cancer - NCI, (2020)."},{"key":"10.1016\/j.biopha.2025.118741_bib29","unstructured":"C. for D.E. and Research, FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer, FDA, (2024)."},{"key":"10.1016\/j.biopha.2025.118741_bib30","unstructured":"Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer, (2023)."},{"key":"10.1016\/j.biopha.2025.118741_bib31","unstructured":"C. for D.E. and Research, FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors, FDA, (2024)."},{"key":"10.1016\/j.biopha.2025.118741_bib32","unstructured":"FDA Grants Accelerated Approval to Adagrasib With Cetuximab for KRAS G12C-Mutated Colorectal Cancer, Oncol. News Cent., (2024)."},{"key":"10.1016\/j.biopha.2025.118741_bib33","unstructured":"C. for D.E. and Research, FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer, FDA, (2025)."},{"key":"10.1016\/j.biopha.2025.118741_bib34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/bjc.2017.37","article-title":"Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer","volume":"116","author":"Jones","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib35","article-title":"Drug resistance in colorectal cancer: an epigenetic overview","volume":"1876","author":"Luo","year":"2021","journal-title":"Biochim. Biophys. Acta BBA Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib36","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s43018-023-00595-y","article-title":"Cancer cell plasticity during tumor progression, metastasis and response to therapy","volume":"4","author":"P\u00e9rez-Gonz\u00e1lez","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib37","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1136\/gutjnl-2016-311447","article-title":"Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture","volume":"66","author":"Grillet","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2025.118741_bib38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2025.118741_bib39","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118741_bib40","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1111\/febs.15690","article-title":"Translation initiation and its relevance in colorectal cancer","volume":"288","author":"Minnee","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.biopha.2025.118741_bib41","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1158\/2159-8290.CD-20-0652","article-title":"MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression","volume":"11","author":"Knight","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118741_bib42","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13046-019-1178-z","article-title":"Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer","volume":"38","author":"Chen","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118741_bib43","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.bbrc.2018.06.150","article-title":"Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer","volume":"503","author":"Xi","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2025.118741_bib44","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41586-018-0243-7","article-title":"Codon-specific translation reprogramming promotes resistance to targeted therapy","volume":"558","author":"Rapino","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118741_bib45","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3390\/cells9112361","article-title":"Ribosome biogenesis alterations in colorectal cancer","volume":"9","author":"Nait Slimane","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118741_bib46","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib47","doi-asserted-by":"crossref","first-page":"14815","DOI":"10.3390\/ijms241914815","article-title":"Role of epithelial to mesenchymal transition in colorectal cancer","volume":"24","author":"Lu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118741_bib48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12032-021-01488-9","article-title":"Cancer stem cells in colorectal cancer and the association with chemotherapy resistance","volume":"38","author":"Lei","year":"2021","journal-title":"Med. Oncol. North. Lond. Engl."},{"key":"10.1016\/j.biopha.2025.118741_bib49","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41388-018-0480-0","article-title":"Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer","volume":"38","author":"Nakano","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118741_bib50","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41467-019-09898-0","article-title":"MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer","volume":"10","author":"Zhan","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118741_bib51","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/cam4.2004","article-title":"Long noncoding RNA and mRNA profiling in cetuximab-resistant colorectal cancer cells by RNA sequencing analysis","volume":"8","author":"Jing","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.biopha.2025.118741_bib52","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1158\/1078-0432.CCR-19-1266","article-title":"Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas","volume":"26","author":"Capdevila","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118741_bib53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/carcin\/bgz199","article-title":"Temporal DNA methylation pattern and targeted therapy in colitis-associated cancer","volume":"41","author":"Li","year":"2020","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.biopha.2025.118741_bib54","unstructured":"Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription | Cancer Chemotherapy and Pharmacology, (n.d.)."},{"key":"10.1016\/j.biopha.2025.118741_bib55","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/gutjnl-2014-308392","article-title":"Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt\/\u03b2-catenin signalling pathway via suppression of activator protein 2\u03b1","volume":"65","author":"Ma","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2025.118741_bib56","article-title":"MLH1 promoter methylation frequency in colorectal cancer patients and related clinicopathological and molecular features","volume":"8","author":"Li","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.biopha.2025.118741_bib57","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1038\/bjc.2013.251","article-title":"The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis","volume":"108","author":"Xing","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib58","doi-asserted-by":"crossref","first-page":"46468","DOI":"10.18632\/oncotarget.17576","article-title":"APC hypermethylation for early diagnosis of colorectal cancer: a meta-analysis and literature review","volume":"8","author":"Liang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118741_bib59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.14218\/GE.2023.00039S","article-title":"Potential epigenetic modifiers targeting the alteration of methylation in colorectal cancer","volume":"23","author":"Jaafari","year":"2024","journal-title":"Gene Expr."},{"key":"10.1016\/j.biopha.2025.118741_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104920","article-title":"Unlocking the therapeutic potential of HDAC inhibitors in colorectal cancer: mechanisms, efficacy, and future perspectives","author":"Wen","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2025.118741_bib61","doi-asserted-by":"crossref","DOI":"10.1172\/JCI183391","article-title":"Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges","volume":"134","author":"Gold","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2025.118741_bib62","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118741_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41592-020-01033-y","article-title":"Method of the Year: spatially resolved transcriptomics","volume":"18","author":"Marx","year":"2021","journal-title":"Nat. Methods"},{"key":"10.1016\/j.biopha.2025.118741_bib64","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.3390\/cancers13184720","article-title":"The role of cancer-associated fibroblasts in cancer invasion and metastasis","volume":"13","author":"Asif","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118741_bib65","doi-asserted-by":"crossref","first-page":"1610350","DOI":"10.3389\/pore.2022.1610350","article-title":"Cancer-associated stromal fibroblast-derived transcriptomes predict poor clinical outcomes and immunosuppression in colon cancer","volume":"28","author":"Wang","year":"2022","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.biopha.2025.118741_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00063","article-title":"Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer","volume":"5","author":"Tommelein","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib67","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc2618","article-title":"Microenvironmental regulation of metastasis","volume":"9","author":"Joyce","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib68","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41423-023-01061-6","article-title":"Roles of macrophages in tumor development: a spatiotemporal perspective","volume":"20","author":"Bied","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.biopha.2025.118741_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004219","article-title":"Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer","volume":"10","author":"Zhu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib70","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.bjc.6605530","article-title":"TNF-\u03b1\/NF-\u03baB\/Snail pathway in cancer cell migration and invasion","volume":"102","author":"Wu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1529847","article-title":"Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction","volume":"16","author":"Verona","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118741_bib72","article-title":"Functional and therapeutic significance of tumor-associated macrophages in colorectal cancer","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215934","article-title":"Multi-functional extracellular vesicles: potentials in cancer immunotherapy","volume":"551","author":"Zhang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2025.118741_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.743556","article-title":"Exosomes: a new pathway for cancer drug resistance","volume":"11","author":"Zhong","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib75","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cytogfr.2023.07.007","article-title":"Exosomes as a modulator of immune resistance in human cancers","volume":"73","author":"Li","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.biopha.2025.118741_bib76","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20176472","article-title":"Exosomes promote cetuximab resistance via the PTEN\/Akt pathway in colon cancer cells","volume":"51","author":"Zhang","year":"2018","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.biopha.2025.118741_bib77","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1080\/15384047.2016.1219815","article-title":"Exosomes secreted from human colon cancer cells influence the adhesion of neighboring metastatic cells: Role of microRNA-210","volume":"17","author":"Bigagli","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2025.118741_bib78","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.omtn.2021.02.022","article-title":"Exosome-transmitted miRNA-335-5p promotes colorectal cancer invasion and metastasis by facilitating EMT via targeting RASA1","volume":"24","author":"Sun","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2025.118741_bib79","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.ymthe.2021.02.006","article-title":"Tumor-derived exosomal microRNA-106b-5p activates EMT-cancer cell and M2-subtype TAM interaction to facilitate CRC metastasis","volume":"29","author":"Yang","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2025.118741_bib80","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.ymthe.2021.02.006","article-title":"Tumor-derived exosomal microRNA-106b-5p activates EMT-cancer cell and M2-subtype TAM interaction to facilitate CRC metastasis","volume":"29","author":"Yang","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2025.118741_bib81","doi-asserted-by":"crossref","first-page":"10622","DOI":"10.3390\/ijms241310622","article-title":"Baseline expression of exosomal miR-92a-3p and miR-221-3p could predict the response to first-line chemotherapy and survival in metastatic colorectal cancer","volume":"24","author":"Gherman","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118741_bib82","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13046-020-01570-6","article-title":"Exosomal miRNAs in tumor microenvironment","volume":"39","author":"Tan","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118741_bib83","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3390\/cancers15041107","article-title":"Extracellular vesicles in colorectal cancer: from tumor growth and metastasis to biomarkers and nanomedications","volume":"15","author":"Kotelevets","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118741_bib84","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.3390\/biomedicines11092401","article-title":"Multi-faceted role of cancer-associated adipocytes in colorectal cancer","volume":"11","author":"Grigora\u0219","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118741_bib85","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1038\/s41467-024-48179-3","article-title":"Dysfunctional adipocytes promote tumor progression through YAP\/TAZ-dependent cancer-associated adipocyte transformation","volume":"15","author":"Song","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118741_bib86","doi-asserted-by":"crossref","first-page":"37534","DOI":"10.1038\/srep37534","article-title":"Hypoxia-induced vasculogenic mimicry formation in human colorectal cancer cells: involvement of HIF-1a, Claudin-4, and E-cadherin and Vimentin","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118741_bib87","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-020-01288-1","article-title":"Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments","volume":"20","author":"Wei","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib88","doi-asserted-by":"crossref","DOI":"10.21037\/tcr.2017.12.20","article-title":"Novel mechanisms of chemoresistance by Fusobacterium nucleatum involve not so novel pathways of microRNAs and autophagy","volume":"7","author":"Kc","year":"2018","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118741_bib89","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.cca.2018.09.007","article-title":"The potential of exosomes derived from colorectal cancer as a biomarker","volume":"490","author":"Xiao","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.biopha.2025.118741_bib90","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","article-title":"Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer","volume":"25","author":"Douillard","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib91","unstructured":"S. Arena, G. Siravegna, B. Mussolin, J.D. Kearns, B.B. Wolf, S. Misale, L. Lazzari, A. Bertotti, L. Trusolino, A.A. Adjei, C. Montagut, F.D. Nicolantonio, R. Nering, A. Bardelli, MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations, (n.d.)."},{"key":"10.1016\/j.biopha.2025.118741_bib92","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR\u2013MET bispecific antibody, in diverse models of EGFR Exon 20 Insertion\u2013Driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118741_bib93","doi-asserted-by":"crossref","first-page":"1157596","DOI":"10.3389\/fonc.2023.1157596","article-title":"Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial","volume":"13","author":"Ferreira","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib94","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.3515","article-title":"First-in-human study of ABBV-400, a novel c-Met\u2013targeting antibody-drug conjugate, in advanced solid tumors: results in colorectal cancer","volume":"42","author":"Sharma","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib95","unstructured":"K.P.S. Raghav, A. Hubert, M. Fakih, H. Fang, M.R.N. Aristide, C.B. de Almeida, A. Vasilopoulos, Y. Sui, J.H. Strickler, Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer, (n.d.)."},{"key":"10.1016\/j.biopha.2025.118741_bib96","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.3000","article-title":"First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC)","volume":"42","author":"Kopetz","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib97","unstructured":"CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors, (n.d.)."},{"key":"10.1016\/j.biopha.2025.118741_bib98","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1142\/S0192415X20500354","article-title":"Cinobufacini inhibits colon cancer invasion and metastasis via suppressing Wnt\/\u03b2-catenin signaling pathway and EMT","volume":"48","author":"Wang","year":"2020","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.biopha.2025.118741_bib99","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.20.01225","article-title":"Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer","volume":"38","author":"Cremolini","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib100","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118741_bib101","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","article-title":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118741_bib102","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/fon-2022-1249","article-title":"SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H\/dMMR BRAFV600E-mutant mCRC","volume":"20","author":"Elez","year":"2024","journal-title":"Future Oncol. Lond. Engl."},{"key":"10.1016\/j.biopha.2025.118741_bib103","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3-kinase \u03b1\u2013selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study","author":"Juric","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib104","doi-asserted-by":"crossref","first-page":"1390452","DOI":"10.3389\/fonc.2024.1390452","article-title":"Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors","volume":"14","author":"Lim","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib105","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118741_bib106","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/bjc.2016.211","article-title":"Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers","volume":"115","author":"Kim","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib107","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/2159-8290.CD-18-0150","article-title":"The clinical impact of the genomic landscape of mismatch repair\u2013deficient cancers","volume":"8","author":"Germano","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118741_bib108","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib109","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair\u2013deficient\/microsatellite instability\u2013high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib110","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.3390\/cancers15215124","article-title":"Implications of rectal cancer radiotherapy on the immune microenvironment: allies and foes to therapy resistance and patients\u2019 outcome","volume":"15","author":"Sartorius","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118741_bib111","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1007\/s00262-021-02986-5","article-title":"A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186","volume":"70","author":"Herting","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2025.118741_bib112","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002844","article-title":"PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer","volume":"9","author":"Stein","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib113","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/1078-0432.CCR-19-2625","article-title":"Inhibition of MDSC trafficking with SX-682, a CXCR1\/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models","volume":"26","author":"Greene","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118741_bib114","unstructured":"M.D. Anderson Cancer Center, Phase Ib\/II Trial of SX-682 in Combination With Nivolumab for Refractory RAS Mutated (RAS) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (STOPTRAFFIC-1), clinicaltrials.gov, 2024."},{"key":"10.1016\/j.biopha.2025.118741_bib115","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2025.118741_bib116","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e15572","article-title":"A phase 1 dose escalation study of a novel coupled CAR T cell therapy, GCC19CART, for patients with metastatic colorectal cancer","volume":"42","author":"Schlechter","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978195","article-title":"CAR T-cells for colorectal cancer immunotherapy: ready to go?","volume":"13","author":"Ghazi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118741_bib118","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.7150\/jca.50509","article-title":"CAR-T cells for colorectal cancer: target-selection and strategies for improved activity and safety","volume":"12","author":"Li","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib119","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.biopha.2025.118741_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.942235","article-title":"Colorectal cancer vaccines: the current scenario and future prospects","volume":"13","author":"Jia","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118741_bib121","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw6071","article-title":"A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer","volume":"6","author":"Ni","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2025.118741_bib122","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1158\/0008-5472.CAN-20-1072","article-title":"A genetic vaccine encoding shared cancer neoantigens to treat tumors with microsatellite instability","volume":"80","author":"Leoni","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118741_bib123","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.biopha.2018.08.109","article-title":"Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: current research status and updates","volume":"107","author":"Guo","year":"2018","journal-title":"Biomed. Pharm. Biomed. Pharm."},{"key":"10.1016\/j.biopha.2025.118741_bib124","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12916-015-0278-7","article-title":"New horizons in tumor microenvironment biology: challenges and opportunities","volume":"13","author":"Chen","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.biopha.2025.118741_bib125","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc2714","article-title":"Environment-mediated drug resistance: a major contributor to minimal residual disease","volume":"9","author":"Meads","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib126","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","article-title":"Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer","volume":"6","author":"Wu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2025.118741_bib127","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1111\/cas.14526","article-title":"Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer","volume":"111","author":"Hong","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2025.118741_bib128","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1158\/1078-0432.CCR-17-1283","article-title":"The immune-microenvironment confers chemoresistance of colorectal cancer through macrophage-derived IL6","volume":"23","author":"Yin","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118741_bib129","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118741_bib130","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-024-02551-2","article-title":"Implantation of engineered adipocytes suppresses tumor progression in cancer models","author":"Nguyen","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2025.118741_bib131","article-title":"Glucagon enhances chemotherapy efficacy by inhibition of tumor vessels in colorectal cancer","volume":"11","author":"Xu","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biopha.2025.118741_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1030745","article-title":"Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer","volume":"13","author":"Hou","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118741_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1298264","article-title":"Dissecting the role of the gut microbiome and fecal microbiota transplantation in radio- and immunotherapy treatment of colorectal cancer","volume":"13","author":"Van Dingenen","year":"2023","journal-title":"Front. Cell. Infect. Microbiol"},{"key":"10.1016\/j.biopha.2025.118741_bib134","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.3748\/wjg.v28.i27.3370","article-title":"Probiotics and postbiotics in colorectal cancer: Prevention and complementary therapy","volume":"28","author":"Kvakova","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.118741_bib135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib136","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2211775119","article-title":"Synthetical lethality of Werner helicase and mismatch repair deficiency is mediated by p53 and PUMA in colon cancer","volume":"119","author":"Hao","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2025.118741_bib137","article-title":"The biological essence of synthetic lethality: bringing new opportunities for cancer therapy, MedComm","volume":"3","author":"Ge","year":"2024","journal-title":"Oncol"},{"key":"10.1016\/j.biopha.2025.118741_bib138","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.21.01435","article-title":"Inhibition of WEE1 is effective in TP53 - and RAS -mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring","volume":"39","author":"Seligmann","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib139","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: a brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.biopha.2025.118741_bib140","doi-asserted-by":"crossref","first-page":"13264","DOI":"10.3390\/ijms252413264","article-title":"Synergistic effects of the combination of alpelisib (PI3K Inhibitor) and ribociclib (CDK4\/6 Inhibitor) in preclinical colorectal cancer models","volume":"25","author":"Aslam","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118741_bib141","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2023.2223388","article-title":"Preclinical evaluation of the CDK4\/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer","volume":"24","author":"Lee","year":"2023","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2025.118741_bib142","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS1113","article-title":"Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced\/recurrent breast cancer (B2151009; NCT02684032)","volume":"35","author":"Forero-Torres","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib143","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1470-2045(24)00034-2","article-title":"Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study","volume":"25","author":"Layman","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib144","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/oncolo\/oyac222","article-title":"Phase II single-arm study of palbociclib and cetuximab rechallenge in patients with KRAS\/NRAS\/BRAF wild-type colorectal cancer","volume":"27","author":"Sorah","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2025.118741_bib145","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jcmgh.2022.07.005","article-title":"Additive effect of CD73 inhibitor in colorectal cancer treatment With CDK4\/6 inhibitor through regulation of PD-L1","volume":"14","author":"Noh","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118741_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1177466","article-title":"Characteristics and molecular mechanism of drug-tolerant cells in cancer: a review","volume":"13","author":"Liang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib147","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118741_bib148","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13046-023-02789-9","article-title":"SENP5 promotes homologous recombination-mediated DNA damage repair in colorectal cancer cells through H2AZ deSUMOylation","volume":"42","author":"Liu","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118741_bib149","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000361","article-title":"Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis","volume":"3","author":"Poggio","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.biopha.2025.118741_bib150","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.3390\/cancers14194874","article-title":"Targeting the DNA damage response and DNA repair pathways to enhance radiosensitivity in colorectal cancer","volume":"14","author":"Deng","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118741_bib151","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2468-1253(17)30012-2","article-title":"Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study","volume":"2","author":"Czito","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118741_bib152","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41416-018-0343-z","article-title":"A phase 2 randomised study of veliparib plus FOLFIRI\u00b1bevacizumab versus placebo plus FOLFIRI\u00b1bevacizumab in metastatic colorectal cancer","volume":"120","author":"Gorbunova","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib153","first-page":"97","article-title":"Microsatellite instability in colorectal cancer","volume":"89","author":"de\u2019 Angelis","year":"2018","journal-title":"Acta Bio Med. Atenei Parm."},{"key":"10.1016\/j.biopha.2025.118741_bib154","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1019582","article-title":"Clinicopathological characteristics of high microsatellite instability\/mismatch repair-deficient colorectal cancer: a narrative review","volume":"13","author":"Mei","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118741_bib155","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118741_bib156","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00280-020-04213-x","article-title":"Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair","volume":"87","author":"Ciniero","year":"2021","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.biopha.2025.118741_bib157","doi-asserted-by":"crossref","DOI":"10.1111\/fcp.13043","article-title":"The synergy between alkylating agents and ERCC1-XPF inhibitors is p53 dependent","volume":"39","author":"Ciniero","year":"2025","journal-title":"Fundam. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.118741_bib158","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","article-title":"Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2025.118741_bib159","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib160","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1126\/science.1099390","article-title":"Bacterial persistence as a phenotypic switch","volume":"305","author":"Balaban","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118741_bib161","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2025.118741_bib162","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.342","article-title":"Targeting drug-tolerant cells: a promising strategy for overcoming acquired drug resistance in cancer cells","volume":"4","author":"Song","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.biopha.2025.118741_bib163","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/cas.14316","article-title":"ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer","volume":"111","author":"Kawakami","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2025.118741_bib164","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.7150\/ijbs.25881","article-title":"KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance","volume":"14","author":"Xu","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2025.118741_bib165","first-page":"1","article-title":"Drug-tolerant persister cancer cells","volume":"4","author":"Wang","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.biopha.2025.118741_bib166","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.18632\/oncotarget.23654","article-title":"Distinct histone modifications denote early stress-induced drug tolerance in cancer","volume":"9","author":"Al Emran","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118741_bib167","doi-asserted-by":"crossref","first-page":"9952","DOI":"10.1038\/s41598-019-46346-x","article-title":"Identification of ryuvidine as a KDM5A inhibitor","volume":"9","author":"Mitsui","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118741_bib168","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1158\/1078-0432.CCR-12-1542","article-title":"Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy","volume":"19","author":"Selvakumaran","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118741_bib169","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature13572","article-title":"eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies","volume":"513","author":"Boussemart","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118741_bib170","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1158\/0008-5472.CAN-11-0420","article-title":"Formation of the eIF4F translation\u2013initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors","volume":"71","author":"Zindy","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118741_bib171","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/s41586-022-05043-y","article-title":"Cell\u2013matrix interface regulates dormancy in human colon cancer stem cells","volume":"608","author":"Ohta","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118741_bib172","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s43018-022-00402-0","article-title":"Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy","volume":"3","author":"\u00c1lvarez-Varela","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib173","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.3390\/cells11192929","article-title":"Molecular regulators of embryonic diapause and cancer diapause-like state","volume":"11","author":"Hussein","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118741_bib174","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","article-title":"Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy","volume":"184","author":"Rehman","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2025.118741_bib175","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib176","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118741_bib177","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2020.12.002","article-title":"An Embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence","volume":"39","author":"Dhimolea","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2025.118741_bib178","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1091\/mbc.e08-12-1248","article-title":"Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy","volume":"20","author":"Hosokawa","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.biopha.2025.118741_bib179","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature20578","article-title":"Inhibition of mTOR induces a paused pluripotent state","volume":"540","author":"Bulut-Karslioglu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118741_bib180","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.cmet.2023.07.005","article-title":"The diapause-like colorectal cancer cells induced by SMC4 attenuation are characterized by low proliferation and chemotherapy insensitivity","volume":"35","author":"Sun","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2025.118741_bib181","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41419-023-05916-8","article-title":"Anastasis enhances metastasis and chemoresistance of colorectal cancer cells through upregulating cIAP2\/NF\u03baB signaling","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2025.118741_bib182","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcdb.2023.11.003","article-title":"Persister cell plasticity in tumour drug resistance","volume":"156","author":"McDonald","year":"2024","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2025.118741_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104483","article-title":"Redox signaling in drug-tolerant persister cells as an emerging therapeutic target","volume":"89","author":"Zhang","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/j.biopha.2025.118741_bib184","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.bcp.2004.05.042","article-title":"Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-\u03baB and pro-inflammatory gene expression","volume":"68","author":"Rahman","year":"2004","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.biopha.2025.118741_bib185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00018-022-04396-x","article-title":"Mechanisms that regulate the activities of TET proteins","volume":"79","author":"Joshi","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.biopha.2025.118741_bib186","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1172\/JCI96393","article-title":"TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence","volume":"128","author":"Puig","year":"2018","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2025.118741_bib187","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.149","article-title":"Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation","volume":"5","author":"Kang","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2025.118741_bib188","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/biom9110735","article-title":"Role of reactive oxygen species in cancer progression: molecular mechanisms and recent advancements","volume":"9","author":"Aggarwal","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2025.118741_bib189","article-title":"Oxidative stress and cellular senescence: roles in tumor progression and therapeutic opportunities, MedComm","volume":"3","author":"Jin","year":"2024","journal-title":"Oncol"},{"key":"10.1016\/j.biopha.2025.118741_bib190","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.gendis.2020.11.019","article-title":"Ferroptosis as a novel form of regulated cell death: implications in the pathogenesis, oncometabolism and treatment of human cancer","volume":"9","author":"Pu","year":"2020","journal-title":"Genes Dis."},{"key":"10.1016\/j.biopha.2025.118741_bib191","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3389\/fphar.2018.01371","article-title":"RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer","volume":"9","author":"Sui","year":"2018","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2025.118741_bib192","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature23007","article-title":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","volume":"547","author":"Viswanathan","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118741_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119486","article-title":"Triggered ferroptotic polymer micelles for reversing multidrug resistance to chemotherapy","volume":"223","author":"Gao","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2025.118741_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114863","article-title":"The first ADC bearing the ferroptosis inducer RSL3 as a payload with conservation of the fragile electrophilic warhead","volume":"244","author":"Nguyen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118741_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102703","article-title":"The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1","volume":"62","author":"Cheff","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.biopha.2025.118741_bib196","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3390\/antiox11050971","article-title":"Auranofin and pharmacologic ascorbate as radiomodulators in the treatment of pancreatic cancer","volume":"11","author":"Steers","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.biopha.2025.118741_bib197","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12672-021-00439-0","article-title":"The gold complex auranofin: new perspectives for cancer therapy","volume":"12","author":"Abdalbari","year":"2021","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib198","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41418-022-01096-8","article-title":"Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation","volume":"30","author":"M\u00fcller","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2025.118741_bib199","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/nm.4399","article-title":"Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells","volume":"23","author":"Kuntz","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118741_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114760","article-title":"Tigecycline reduces tumorigenesis in colorectal cancer via inhibition of cell proliferation and modulation of immune response","volume":"163","author":"Ruiz-Malag\u00f3n","year":"2023","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2025.118741_bib201","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12885-024-12064-5","article-title":"Regulation of metastatic potential by drug repurposing and mitochondrial targeting in colorectal cancer cells","volume":"24","author":"Mathur","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib202","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3332\/ecancer.2019.935","article-title":"Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse","volume":"13","author":"Murray","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.biopha.2025.118741_bib203","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer","volume":"29","author":"Kotani","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118741_bib204","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1158\/0008-5472.CAN-21-3844","article-title":"Drug-tolerant persister cells in cancer therapy resistance","volume":"82","author":"Dhanyamraju","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118741_bib205","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.actbio.2023.05.043","article-title":"Overcoming tumor microenvironment obstacles: Current approaches for boosting nanodrug delivery","volume":"166","author":"Wang","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.biopha.2025.118741_bib206","article-title":"Glutathione peroxidase 4 as a therapeutic target for anti-colorectal cancer drug-tolerant persister cells","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib207","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","article-title":"Drug-tolerant persister cells in cancer: the cutting edges and future directions","volume":"20","author":"Pu","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib208","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg3049","article-title":"Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer","volume":"15","author":"Li","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2025.118741_bib209","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.gendis.2019.10.013","article-title":"Molecular subtypes of colorectal cancer: an emerging therapeutic opportunity for personalized medicine","volume":"8","author":"Singh","year":"2021","journal-title":"Genes Dis."},{"key":"10.1016\/j.biopha.2025.118741_bib210","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrclinonc.2016.171","article-title":"From tumour heterogeneity to advances in precision treatment of colorectal cancer","volume":"14","author":"Punt","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib211","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2025.118741_bib212","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","article-title":"Colorectal cancer","volume":"404","author":"Eng","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.biopha.2025.118741_bib213","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-019-0241-1","article-title":"Biomarker-guided therapy for colorectal cancer: strength in complexity","volume":"17","author":"Sveen","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib214","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-019-0241-1","article-title":"Biomarker-guided therapy for colorectal cancer: strength in complexity","volume":"17","author":"Sveen","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-019-0241-1","article-title":"Biomarker-guided therapy for colorectal cancer: strength in complexity","volume":"17","author":"Sveen","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib216","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3390\/biomedicines13081835","article-title":"Precision oncology through dialogue: AI-HOPE-RTK-RAS integrates clinical and genomic insights into RTK-RAS alterations in colorectal cancer","volume":"13","author":"Yang","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118741_bib217","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41419-025-07471-w","article-title":"High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers","volume":"16","author":"Fan","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2025.118741_bib218","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.856575","article-title":"Liquid biopsy and artificial intelligence as tools to detect signatures of colorectal malignancies: a modern approach in patient\u2019s stratification","volume":"12","author":"Ginghina","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib219","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccell.2019.05.013","article-title":"Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer","volume":"36","author":"Woolston","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2025.118741_bib220","article-title":"High-accuracy prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data","volume":"14","author":"Amniouel","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.biopha.2025.118741_bib221","doi-asserted-by":"crossref","first-page":"6654","DOI":"10.1038\/s41467-021-26990-6","article-title":"Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging","volume":"12","author":"Lu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118741_bib222","doi-asserted-by":"crossref","unstructured":"The International Cancer Genome Consortium, International network of cancer genome projects, Nature, 464 (2010) 993\u2013998.","DOI":"10.1038\/nature08987"},{"key":"10.1016\/j.biopha.2025.118741_bib223","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","author":"Chakravarty","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib224","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118741_bib225","unstructured":"Human Tumor Atlas Network (HTAN) - NCI, (2024)."},{"key":"10.1016\/j.biopha.2025.118741_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109979","article-title":"Hallmarks of cancer resistance","volume":"27","author":"Tufail","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.biopha.2025.118741_bib227","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.biopha.2025.118741_bib228","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi8618","article-title":"Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: current research, opportunities, and challenges","volume":"8","author":"Sanz-Garcia","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2025.118741_bib229","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1053\/j.gastro.2022.08.025","article-title":"Quantitative pathologic analysis of digitized images of colorectal carcinoma improves prediction of recurrence-free survival","volume":"163","author":"Pai","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118741_bib230","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.315","article-title":"Applications of multi-omics analysis in human diseases","volume":"4","author":"Chen","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.biopha.2025.118741_bib231","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/14737159.2025.2534962","article-title":"Regulation of biomarker analysis: what can be translated in the clinic?","volume":"25","author":"Diamantopoulos","year":"2025","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.biopha.2025.118741_bib232","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119686","article-title":"Precision medicine in colorectal cancer: leveraging multi-omics, spatial omics, and artificial intelligence","volume":"559","author":"Xu","year":"2024","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"10.1016\/j.biopha.2025.118741_bib233","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.semcancer.2022.12.009","article-title":"Artificial intelligence-based multi-omics analysis fuels cancer precision medicine","volume":"88","author":"He","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.biopha.2025.118741_bib234","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-025-02369-9","article-title":"Current AI technologies in cancer diagnostics and treatment","volume":"24","author":"Tiwari","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2025.118741_bib235","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118741_bib236","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","article-title":"Current advance of nanotechnology in diagnosis and treatment for malignant tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:29:56Z","timestamp":1778754596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225009357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":236,"alternative-id":["S0753332225009357"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118741","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring and bypassing resistance to targeted therapies in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118741"}}